• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
  • Donate
Home / Arthritis News / TNF Inhibitor Use Associated with a Reduced Risk of Myocardial Infarction in Rheumatoid Arthritis Patients?

TNF Inhibitor Use Associated with a Reduced Risk of Myocardial Infarction in Rheumatoid Arthritis Patients?

September 28, 2007 By Arthritis Center

Background:

RA is associated with an increase in cardiovascular (CV) events, such as myocardial infarction (MI) and sudden cardiac death.  Inflammatory cytokines, such as TNF-α, are implicated in atherothrombosis and the RA disease state, potentially explaining the increased risk of CV events in RA.  The use of TNF inhibitors was associated with a reduced risk of cardiovascular events in RA patients in one study, although it is not clear whether these effects are due to unique features of TNF inhibitors or are a consequence of non-specific suppression of inflammation.  Here, Dixon et al (Arthritis Rheum 2007; 56(9): 2905) explore these issues in analyses of participants enrolled in the British Society for Rheumatology Biologics Register (BSRBR).

Methods:

The BSRBR is a registry of patients initiated on biologic therapy in the UK with a parallel comparison cohort of non-TNF inhibitor treated patients enrolled.  Participants undergo a comprehensive baseline assessment and follow-up assessments by questionnaire (to participants and treating rheumatologists) every 6 months thereafter.  For these analyses, only RA patients were included.  Information on incident MIs was gathered from patient report and verified using hospital records and national mortality registries.
Rates of incident MI were compared between TNF-inhibitor treated and untreated groups, and within groups according to response to treatment.  Only first MIs and those occurring while undergoing active treatment were analyzed.

Results:

There were 10,755 RA subjects included in the analyses, of whom 8,659 were treated with TNF inhibitors.  Compared to TNF inhibitor treated subjects, DMARD treated subjects were older (mean age 60 vs 56 years at enrollment; p = 0.002) with a lower proportion of females (72% vs. 76%; p=0.01), lower DAS28 scores (mean 5.0 vs. 6.6; p <0.001), and lower HAQ scores (mean 1.5 vs. 2.1; p<0.001).  Among CV factors in comparison to TNF inhibitor treated subjects, DMARD treated subjects reported prior MI and angina nearly twice as frequently TNF inhibitor treated subjects, were significantly more likely to be receiving lipid lowering and anti-platelet medications, had a significantly lower proportion of corticosteroid treatment (19.3% vs. 43.7%; p <0.001), and were slightly less frequently treated with NSAIDs (62% vs. 66%; p = 0.001).
Median follow-up time was relatively short; 1.66 years in the TNF inhibitor cohort and 1.34 years in the DMARD cohort.  During follow-up, 63 verified MIs were reported in the TNF inhibitor cohort (4.8 per 1000 person-years) compared to 17 in the DMARD cohort (5.9 per 1000 person-years).  After adjusting for demographic and cardiovascular risk factors, there was no difference in the adjusted rate of MI between the TNF inhibitor and DMARD groups.

Among the TNF inhibitor treated subjects (n=7,515), 5,877 (78%) were classified as responders to therapy at 6 months.  The incidence rate of MI was 3.5 per 1000 person-years in 6-month responders (95% CI 2.5 – 4.9) vs. 9.4 per 1000 person-years in non-responders (95% CI 5.5-15.0).  After adjusting for demographic and cardiovascular risk factors, there was a 64% reduction in MI risk in 6-month TNF inhibitor responders compared to non-responders (95% CI 0.19 – 0.69).  In gender stratified analyses, reduced MI risk was seen in male and female responders vs. non-responders; however, the risk reduction was significantly lower in men only.

Conclusions:

TNF inhibitor use was not uniquely associated with a reduction in incident MI over the risk reduction observed with response to treatment.

Editorial Comment:

These data suggest that there may be no unique benefit to TNF inhibitor therapy for MI reduction in RA patients over and above their ability to normalize disease activity.  This is not discouraging, as it suggests that any DMARD regimen effective at managing disease activity in an individual patient will confer some degree of CV protective benefit.  The observation that response to TNF inhibitor therapy is associated with a reduction in MI risk is consistent with other reports demonstrating CV mortality reduction with methotrexate use.  Inflammation is general, and inflammatory cytokines like TNF-α in particular, are associated with destabilization of vulnerable atherosclerotic plaques; a potential link between inflammation in RA and MI.  However, the mechanisms of inflammation associated atherogenesis may be different from those of atherothrombosis, and thus, more study is needed to clarify the role of RA therapeutics on CV disease risk.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Recent News

Exercise Tips for Arthritis Patients

How Does Exercise Affect my Joints? How Frequently Should I Be Exercising? Should I Lose Weight for Exercise to be

Risks and Benefits of Biologic Medications

Victoria Ruffing, RN, BC, Director of Patient Education at the Johns Hopkins Arthritis Center, shares the risks and benefits of biologic for

How to Manage Rheumatoid Arthritis Flares

Through research, doctors have a clearer understanding of how flares can impact a patient on a personal and emotional level. Dr. Uzma Haque

Complementary & Alternative Medicines for Psoriatic Arthritis

There are many complementary & alternative medicines and practices that have been found to be beneficial in curbing arthritis pain,

I can’t be a runner because I have Rheumatoid Arthritis (RA), right?

Dr. Manno discusses running and Rheumatoid Arthritis. Is it an option for the RA patient?

News Categories

  • Ankylosing Spondylitis News
  • Fibromyalgia News
  • Gout News
  • Lupus News
  • Osteoarthritis News
  • Osteoporosis News
  • Psoriatic Arthritis News
  • Rheumatoid Arthritis News
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2023 Johns Hopkins Arthritis Center
Patient Privacy